# BioResearchAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioresearchai

- Industry: Software
- Headquarters: Seoul, South Korea
- Total disclosed funding: $0.8M
- Latest round: Seed (Nov 18, 2022)
- Investors on record: 3

## About

Based in Seoul, South Korea, and founded in 2022 by CEO Lee Sang-Yoon, BioResearchAI operates as a provider of cloud-based software that automates the sorting process of past research in the pharmaceutical, biotechnology, and healthcare industries. In November 2022, BioResearchAI raised KRW 10 billion in seed funding from Crit Ventures, KAIST Youth Startup Investment Holdings, and Sopoong Ventures. In July 2023, BioResearchAI raised seed funding from a new investor Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program. Financial terms of the deal were not disclosed. The company provides machine learning (ML) powered software that automates pharmaceutical bio research that in the past researchers used to classify vast amounts of papers themselves. The software selects articles, papers, clinical information, patents, conference materials, and FDA approval data, builds a database, and delivers the latest deals, regulations, and research and development status according to customer interests. The firm’s client base includes pharmaceutical companies, biotechs, medical device developers, and healthcare companies. BioResearchAI plans to launch the global paid service in earnest in the middle of 2023.

## Funding rounds

- Seed, Nov 18, 2022, $0.8M — Sopoong Ventures, KAIST Ventures, Crit Ventures

## Investors

- Sopoong Ventures (https://capitalatlas.ai/funds/sopoong-ventures) — Seed
- KAIST Ventures (https://capitalatlas.ai/funds/kaist-ventures) — Seed
- Crit Ventures (https://capitalatlas.ai/funds/crit-ventures) — Seed